[Featured Stock] Aptabio Hits Upper Limit After Successful Phase 2 Clinical Trial of Diabetic Nephropathy Drug Candidate

[Asia Economy Reporter Lee Seon-ae] Aptabio has entered the upper price limit during trading. On the 29th at 2:10 PM, Aptabio recorded the upper limit price of 22,000 KRW, soaring by the maximum price limit of 29.79%.

This follows Aptabio's announcement that it confirmed the efficacy and safety in the global Phase 2 clinical trial of the diabetic nephropathy drug candidate 'Aisujinaxib (APX-115)'.

Diabetic nephropathy is a disease that causes structural and functional damage to the kidneys due to various causes such as hyperglycemia, and is known as a cause of renal failure.

Aptabio evaluated efficacy and safety by administering placebo and Aisujinaxib respectively to 140 patients across four European countries.

The study results showed that the effect of Aisujinaxib was better compared to placebo, and safety was also confirmed, the company explained.

An Aptabio official said, "The current diabetic nephropathy treatment market is worth 10 trillion KRW, which is limited to mild cases, and there is no treatment for severe cases yet, so the market potential is very high, and APX-115 is in a very advantageous position to capture the global market," adding, "With the significance secured in this Phase 2 clinical trial, negotiations for technology export with global big pharma are rapidly progressing."

Meanwhile, Aptabio is a company developing new drugs for intractable diseases based on platform technology, established in 2009.

This content was produced with the assistance of AI translation services.